Trial Profile
A 12-week, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of QAW039 When Added to Standard-of-care Asthma Therapy in Patients With Uncontrolled Asthma
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Fevipiprant (Primary)
- Indications Asthma
- Focus Registrational; Therapeutic Use
- Acronyms ZEAL; ZEAL-2
- Sponsors Novartis; Novartis Healthcare; Novartis Pharma A.G.; Novartis Pharmaceuticals
- 17 Feb 2020 Primary endpoint has not been met. (Change From Baseline in Pre-dose FEV1)
- 17 Feb 2020 Results published in the ClinicalTrials.gov Trial Registry
- 16 Feb 2020 Results published in the European Clinical Trials Database Trial Registry